• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎与血管紧张素转换酶 2 的关系:范围综述。

Relationship Between COVID-19 and Angiotensin-Converting Enzyme 2: A Scoping Review.

机构信息

Student Research Committee, Nursing Faculty, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Trauma Research Center, Nursing Faculty, Baqiyatallah University of Medical Sciences, Tehran, Iran.

出版信息

Adv Exp Med Biol. 2021;1321:53-68. doi: 10.1007/978-3-030-59261-5_5.

DOI:10.1007/978-3-030-59261-5_5
PMID:33656713
Abstract

Following the outbreaks of SARS-CoV in 2002 and MERS-CoV in 2012, the COVID-19 pandemic caused by the SARS-CoV-2 virus has become an increasing threat to human health around the world. Numerous studies have shown that SARS-CoV-2 appears similar to the SARS-CoV as it uses angiotensin converting enzyme 2 (ACE2) as a receptor to gain entry into cells. The main aims of this scoping review were to identify the primary hosts of coronaviruses, the relationship between the receptor binding domain of coronaviruses and ACE2, the organ specificity of ACE2 expression compared with clinical manifestations of the disease, and to determine if this information can be used in the development of novel treatment approaches for the COVID-19 pandemic.

摘要

继 2002 年 SARS-CoV 和 2012 年 MERS-CoV 爆发后,由 SARS-CoV-2 病毒引起的 COVID-19 大流行已成为全球人类健康的日益威胁。大量研究表明,SARS-CoV-2 与 SARS-CoV 相似,因为它使用血管紧张素转换酶 2(ACE2)作为受体进入细胞。本范围综述的主要目的是确定冠状病毒的主要宿主,冠状病毒的受体结合域与 ACE2 的关系,ACE2 表达与疾病临床表现的器官特异性,并确定这些信息是否可用于开发针对 COVID-19 大流行的新型治疗方法。

相似文献

1
Relationship Between COVID-19 and Angiotensin-Converting Enzyme 2: A Scoping Review.新型冠状病毒肺炎与血管紧张素转换酶 2 的关系:范围综述。
Adv Exp Med Biol. 2021;1321:53-68. doi: 10.1007/978-3-030-59261-5_5.
2
Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)对动物血管紧张素转换酶2受体的广泛及差异性利用
J Virol. 2020 Aug 31;94(18). doi: 10.1128/JVI.00940-20.
3
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
4
Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.病毒受体ACE2直系同源物的功能和遗传分析揭示了SARS-CoV-2广泛的潜在宿主范围。
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12). doi: 10.1073/pnas.2025373118.
5
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.SARS-CoV-2 大流行和研究空白:了解 SARS-CoV-2 与 ACE2 受体的相互作用及其对治疗的影响。
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
6
Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.冠状病毒刺突蛋白和宿主 ACE2 受体的组成和分化预测了 SARS-CoV-2 的潜在中间宿主。
J Med Virol. 2020 Jun;92(6):595-601. doi: 10.1002/jmv.25726. Epub 2020 Mar 11.
7
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.新型冠状病毒受体识别:基于 SARS 冠状病毒长达十年结构研究的分析。
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
8
Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.竞争性 SARS-CoV-2 血清学研究表明,大多数针对刺突受体结合域的抗体竞争与 ACE2 结合。
mSphere. 2020 Sep 16;5(5):e00802-20. doi: 10.1128/mSphere.00802-20.
9
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.SARS-CoV-2 与其他冠状病毒与 ACE(血管紧张素转换酶)-2 作为其主要受体的相互作用:治疗意义。
Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27.
10
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.一种使用 ACE2 受体的蝙蝠 SARS 样冠状病毒的分离与鉴定
Nature. 2013 Nov 28;503(7477):535-8. doi: 10.1038/nature12711. Epub 2013 Oct 30.

引用本文的文献

1
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)亚单位疫苗的皮肤给药可诱导针对关注变异株的免疫原性。
Vaccines (Basel). 2022 Apr 8;10(4):578. doi: 10.3390/vaccines10040578.
2
COVID-19 and the liver: What do we know so far?新型冠状病毒肺炎与肝脏:我们目前了解到什么?
World J Hepatol. 2021 May 27;13(5):522-532. doi: 10.4254/wjh.v13.i5.522.
3
Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins.

本文引用的文献

1
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.吸入修饰的血管紧张素转换酶2(ACE2)作为诱饵减轻新型冠状病毒2(SARS-CoV-2)感染。
N Z Med J. 2020 May 22;133(1515):112-118.
2
Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?穿山甲是否是 2019 新型冠状病毒(SARS-CoV-2)的中间宿主?
PLoS Pathog. 2020 May 14;16(5):e1008421. doi: 10.1371/journal.ppat.1008421. eCollection 2020 May.
3
Gastrointestinal and Liver Manifestations of COVID-19.新型冠状病毒肺炎的胃肠道和肝脏表现
药物和针对病毒表面糖蛋白的疫苗的季节性和新兴呼吸道病毒的干预策略。
Viruses. 2021 Apr 6;13(4):625. doi: 10.3390/v13040625.
J Clin Exp Hepatol. 2020 May-Jun;10(3):263-265. doi: 10.1016/j.jceh.2020.03.001. Epub 2020 Apr 1.
4
Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019.新型冠状病毒病 2019 的肺损伤和心血管并发症的病理生理特征和治疗方法。
Cardiovasc Pathol. 2020 Jul-Aug;47:107228. doi: 10.1016/j.carpath.2020.107228. Epub 2020 Apr 17.
5
COVID-19 pathophysiology: A review.新型冠状病毒肺炎的病理生理学:综述。
Clin Immunol. 2020 Jun;215:108427. doi: 10.1016/j.clim.2020.108427. Epub 2020 Apr 20.
6
The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study.单细胞转录组研究揭示 SARS-CoV-2 受体 ACE2 在母胎界面和胎儿器官中的表达。
PLoS One. 2020 Apr 16;15(4):e0230295. doi: 10.1371/journal.pone.0230295. eCollection 2020.
7
The proximal origin of SARS-CoV-2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的近端起源。
Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9.
8
[Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].基于临床经验和分子对接快速建立中医药防治新型冠状病毒肺炎方案
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1213-1218. doi: 10.19540/j.cnki.cjcmm.20200206.501.
9
Coronavirus disease 2019 (COVID-19): current status and future perspectives.新型冠状病毒病 2019(COVID-19):现状和未来展望。
Int J Antimicrob Agents. 2020 May;55(5):105951. doi: 10.1016/j.ijantimicag.2020.105951. Epub 2020 Mar 29.
10
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)进入细胞依赖于 ACE2 和 TMPRSS2,可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.